These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7587102)

  • 1. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin.
    Dameron KM; Volpert OV; Tainsky MA; Bouck N
    Cold Spring Harb Symp Quant Biol; 1994; 59():483-9. PubMed ID: 7587102
    [No Abstract]   [Full Text] [Related]  

  • 2. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.
    Dameron KM; Volpert OV; Tainsky MA; Bouck N
    Science; 1994 Sep; 265(5178):1582-4. PubMed ID: 7521539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts.
    Stellmach V; Volpert OV; Crawford SE; Lawler J; Hynes RO; Bouck N
    Eur J Cancer; 1996 Dec; 32A(14):2394-400. PubMed ID: 9059327
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1.
    Hsu SC; Volpert OV; Steck PA; Mikkelsen T; Polverini PJ; Rao S; Chou P; Bouck NP
    Cancer Res; 1996 Dec; 56(24):5684-91. PubMed ID: 8971176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression.
    Volpert OV; Stellmach V; Bouck N
    Breast Cancer Res Treat; 1995; 36(2):119-26. PubMed ID: 8534861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p53 mutation "gradient effect" and its clinical implications.
    Zambetti GP
    J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
    Gu J; Kawai H; Wiederschain D; Yuan ZM
    Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and imaging surveillance in Li-Fraumeni syndrome.
    Raskind WH; Hisama FM; Bennett RL
    Lancet Oncol; 2016 Nov; 17(11):e472. PubMed ID: 27819239
    [No Abstract]   [Full Text] [Related]  

  • 9. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.
    Good DJ; Polverini PJ; Rastinejad F; Le Beau MM; Lemons RS; Frazier WA; Bouck NP
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6624-8. PubMed ID: 1697685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and imaging surveillance in Li-Fraumeni syndrome - Authors' reply.
    Villani A; Malkin D
    Lancet Oncol; 2016 Nov; 17(11):e473. PubMed ID: 27819240
    [No Abstract]   [Full Text] [Related]  

  • 11. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
    Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
    Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
    Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
    Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
    Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
    Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
    Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
    Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family.
    Barel D; Avigad S; Mor C; Fogel M; Cohen IJ; Zaizov R
    Cancer Genet Cytogenet; 1998 May; 103(1):1-6. PubMed ID: 9595036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
    Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
    Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression.
    Grossfeld GD; Ginsberg DA; Stein JP; Bochner BH; Esrig D; Groshen S; Dunn M; Nichols PW; Taylor CR; Skinner DG; Cote RJ
    J Natl Cancer Inst; 1997 Feb; 89(3):219-27. PubMed ID: 9017002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex replication error causes p53 mutation in a Li-Fraumeni family.
    Strauss EA; Hosler MR; Herzog P; Salhany K; Louie R; Felix CA
    Cancer Res; 1995 Aug; 55(15):3237-41. PubMed ID: 7614454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Li-Fraumeni syndrome: a p53 family affair.
    Iwakuma T; Lozano G; Flores ER
    Cell Cycle; 2005 Jul; 4(7):865-7. PubMed ID: 15917654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
    Evans SC; Lozano G
    Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.